Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.66 Analyst target: $9.17 Upside: 150.55%
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.